Today, Dr. Michelle McMurry-Heath informed the Biotechnology Innovation Organization (BIO) Executive Committee that she is stepping down from her position as President and Chief Executive Officer effective October 11, 2022, and she has agreed to instead serve as Advisor to the Executive Committee, providing advice and assistance on key BIO initiatives.
“The Board of Directors thanks Dr. McMurry-Heath for her service to BIO as CEO and appreciates her continued work with BIO in the months ahead in support of biotech innovation and the patients the organization serves,” said Paul Hastings, Chair of BIO Executive Committee & Board of Directors.
“Dr. McMurry-Heath has earned widespread admiration and recognition as a voice for the biotech industry, broadening awareness of key industry imperatives, such as supporting life-saving biotech innovation and overcoming the challenges of COVID-19, and advancing initiatives to increase diversity and inclusivity across the biotech industry,” said Ted W. Love, M.D., Vice-Chair of BIO Executive Committee & Board of Directors.
BIO will identify an interim CEO and launch a search for a successor.
